PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
22.84%
Net income growth 1.25-1.5x CRVO's 16.56%. Bruce Berkowitz would verify whether cost discipline or revenue gains drive the outperformance.
7.12%
Some D&A expansion while CRVO is negative at -4.67%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
-26.57%
Both cut yoy SBC, with CRVO at -1.51%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-21.66%
Negative yoy working capital usage while CRVO is 137.34%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy AP while CRVO is 34.25%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
161.21%
Lower 'other working capital' growth vs. CRVO's 399.57%. David Dodd would see fewer unexpected short-term demands on cash.
200.00%
Lower 'other non-cash' growth vs. CRVO's 1643.66%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
22.87%
Operating cash flow growth similar to CRVO's 22.78%. Walter Schloss would see parallel improvements or market conditions in cash generation.
-183.51%
Negative yoy CapEx while CRVO is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-183.51%
We reduce yoy invests while CRVO stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-107.12%
Both yoy lines negative, with CRVO at -100.00%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.